Pentixapharm Holding AG (FRA:PTP)

Market Cap	50.56M -26.0%
Revenue (ttm)	526.00K -74.4%
Net Income	-16.51M
EPS	-0.67
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	81
Open	2.000
Previous Close	2.040
Day's Range	2.000 - 2.080
52-Week Range	1.312 - 3.670
Beta	n/a
RSI	53.67
Earnings Date	Mar 26, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2019
• Employees: 61
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PTP

Financial Performance

In 2025, Pentixapharm Holding AG's revenue was 526,000, a decrease of -74.37% compared to the previous year's 2.05 million. Losses were -16.51 million, 26.4% more than in 2024.